Issue Type: Payer and Supply Chain Economics Favor Higher Cost Drugs
in challenge narrative
-
The Big Problem With High Health Care Deductibles
-
Here Are the 5 Drug Classes with the Biggest Price Gains
-
Why Drugs Cost So Much
-
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
-
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
-
Spending On Prescription Drugs In The US: Where Does All The Money Go?
-
DPL responds to HHS Blueprint (May 16, 2018)